Molecular Imaging

Nuclear imaging, also called molecular imaging, includes positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. This section includes radiopharmaceuticals and tracers, PET-CT, SPECT-CT, and PET-MRI. Molecular imaging includes the field of nuclear medicine, which uses very small amounts of radioactive materials, or radiopharmaceuticals, to diagnose and treat disease.

Comprehensive restoration of legacy machine offers the opportunity for sustainable solution
News | Proton Therapy
IBA Plans Total System Restoration on its First-ever Proton Therapy Installation

October 23, 2023 — IBA, a world leader in particle accelerator technology and the world’s leading provider of proton ...

Time October 23, 2023
arrow
Meilleur Technologies, Inc. announced a research collaboration agreement with the Alzheimer’s Disease Neuroimaging Initiative 4, ADNI4
News | Radiopharmaceuticals and Tracers
Meilleur Technologies Inc. Announces Use of the Next-Generation Amyloid PET Imaging Biomarker, NAV-4694, in the Alzheimer’s Disease Neuroimaging Initiative 4 (ADNI4)

October 20, 2023 — Meilleur Technologies, Inc. announced a research collaboration agreement with the Alzheimer’s Disease ...

Time October 20, 2023
arrow
New company will advance Actinium-225 technologies
News | Radiopharmaceuticals and Tracers
ITM and CNL Announce the Launch of Actineer, a New Joint Venture in the Global Production of Actinium-225

October 18, 2023 —ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Canadian ...

Time October 18, 2023
arrow
68Ga-ABY-025 PET/CT and 18F-FDG PET/CT images at baseline with 18F-FDG PET/CT follow-up after 2 cycles of treatment in biopsy-confirmed HER2-positive disease
News | Breast Imaging
Whole-body PET/CT Predicts Response to HER2-targeted Therapy in Metastatic Breast Cancer Patients

October 11, 2023 — A new imaging agent, 68Ga-ABY-025, can predict early metabolic response to human epidermal growth ...

Time October 11, 2023
arrow
POSLUMA (flotufolastat F 18) PET/CT image showing uptake in the prostate gland, consistent with primary prostate cancer.
News | Radiopharmaceuticals and Tracers
Additional Results of POSLUMA (Flotufolastat F 18) Performance in Newly Diagnosed, High-risk Prostate Cancer Patients Presented at ASTRO

October 5, 2023 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time October 05, 2023
arrow
A the COVID-19 public health emergency continues to evolve, SNMMI issues updated guidance
News | SNMMI
SNMMI Issues Updated Statement: COVID-19 and V/Q Lung Studies

September 18, 2023 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI), as a professional society ...

Time September 18, 2023
arrow
The clinical study of Positron’s Affinity PET-CT is designed to provide key information that evaluate the new system and its full capabilities with multiple radiopharmaceuticals and new coronary flow software applications that will enhance physician’s diagnostic analysis
News | PET-CT
Positron Corporation Announces Start of Clinical Study of Affinity PET-CT Device

September 8, 2023 — Positron Corporation, a leading molecular imaging medical device company, is pleased to announce ...

Time September 08, 2023
arrow
NorthStar’s high purity non-carrier added (n.c.a.) Ac-225 to be used in Curadh’s molecularly targeted radiation (MTR) programs for treatment of solid tumors
News | Radiopharmaceuticals and Tracers
NorthStar Medical Radioisotopes and Curadh MTR Announce a Strategic Long Term Supply Agreement for Therapeutic Radioisotope Actinium-225 (Ac-225)

August 31, 2023 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time August 31, 2023
arrow
First participant of cohort 4 of the theranostic CL04 trial investigating 64Cu/67Cu SARTATE in neuroblastoma has been treated at the highest dose cohort of 375MBq/kg body weight using NorthStar’s electron accelerator-produced Cu-67, marking a key milestone in NorthStar’s agreement to exclusively supply Cu-67 to Clarity
News | Radiopharmaceuticals and Tracers
First Participant Treated Using NorthStar Medical Radioisotopes’ Electron Accelerator-produced Copper-67 (Cu-67) in Clarity Pharmaceuticals’ Phase I/IIa Theranostic Clinical Trial Investigating Cu-67 SARTATE for Treatment of Neuroblastoma

August 29, 2023 — NorthStar Medical Radioisotopes, LLC (“NorthStar"), a global innovator in the development, production ...

Time August 29, 2023
arrow
First participant of cohort 4 of the theranostic CL04 trial investigating 64Cu/67Cu SARTATE in neuroblastoma has been treated at the highest dose cohort of 375MBq/kg body weight using NorthStar’s electron accelerator-produced Cu-67, marking a key milestone in NorthStar’s agreement to exclusively supply Cu-67 to Clarity
News | Radiopharmaceuticals and Tracers
Carolina Breast Imaging Specialists, PLLC Is First in Nation to Adopt Groundbreaking Imagio Breast Imaging System for Breast Cancer Diagnosis

August 29, 2023 — Mammograms are an essential part of preventive healthcare, and when an initial review reveals a ...

Time August 29, 2023
arrow
FDA-approved generic for MRI procedures is fully substitutable for Gadavist
News | Contrast Media
Fresenius Kabi Further Expands Radiology Portfolio with Launch of Gadobutrol Injection

August 8, 2023 — Fresenius Kabi announced it has launched Gadobutrol Injection, a generic substitute for the contrast ...

Time August 08, 2023
arrow
Positron Corporation has entered an Novation Agreement with Shenyang Intelligent Neuclear Medical Technology Co, LTD (Intelligent Neuclear Medical), a wholly owned subsidiary of Neusoft Medical Systems (Neusoft.
News | PET-CT
Positron Corporation Enters New Manufacturing & Components Supplier Cooperative with Neusoft Medical Systems Subsidiary for New PET-CT Device

July 25, 2023 — Positron Corporation, a leading molecular imaging medical device company, is pleased to announce that ...

Time July 25, 2023
arrow
Medical society for cancer specialists names 29 exemplary members to its 2023 class of Fellows
News | ASTRO
Radiation Oncology Leaders Awarded ASTRO Fellow Designation

July 20, 2023 — The American Society for Radiation Oncology (ASTRO) selected 29 distinguished members to receive the ...

Time July 20, 2023
arrow
NorthStar’s non-carrier added (n.c.a.) Ac-225 to be used in Bayer’s radiopharmaceutical programs
News | Molecular Imaging
NorthStar Medical Radioisotopes Executes Supply Agreement with Bayer for Therapeutic Radioisotope Actinium-225 (Ac-225)

July 18, 2023 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time July 18, 2023
arrow
With uMI Panorama, United Imaging Continues to Push the Envelope on Whole-Body System Performance
News | PET-CT
United Imaging Introduces Next-Generation PET/CT Systems and Integrated Molecular Technology Platform at SNMMI

July 12, 2023 — United Imaging, a global leader in manufacturing advanced medical imaging and radiotherapy equipment and ...

Time July 12, 2023
arrow
NorthStar’s high purity non-carrier-added (n.c.a.) Ac-225 to be used in advancing Nucleus’ partners radioligand therapies to treat cancer
News | Molecular Imaging
NorthStar Medical Radioisotopes Announces Supply Agreement with Nucleus RadioPharma for Alpha-emitting Therapeutic Radioisotope Actinium-225 (Ac-225)

July 5, 2023 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

Time July 05, 2023
arrow
News | SNMMI
Research Showing Genomics- and Image-Guided Subtyping Refines Characterization of Alzheimer’s Disease Presented at SNMMI 2023

June 29, 2023 — Research presented at the 2023 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging ...

Time June 29, 2023
arrow
News | SNMMI
Prostate Cancer Treatment Study at SNMMI 2023 Finds Improved Patient Outcomes with Personalized Dosing

June 29, 2023 — A study presented this week during the 2023 Society of Nuclear Medicine and Molecular Imaging (SNMMI) ...

Time June 29, 2023
arrow
Molecular imaging with 18F-flubatine PET/MRI has shown that neuroreceptors in the brains of individuals with obesity respond differently to food cues than those in normal-weight individuals, making the neuroreceptors a prime target for obesity treatments and therapy
News | SNMMI
Molecular Imaging Identifies Brain Changes in Response to Food Cues; Offers Insight into Obesity Interventions

June 28, 2023 — Molecular imaging with 18F-flubatine PET/MRI has shown that neuroreceptors in the brains of individuals ...

Time June 28, 2023
arrow
News | SNMMI
Society of Nuclear Medicine and Molecular Imaging Names Helen Nadel, MD, FRCPC, of Stanford, as President, Announces New Officers at SNMMI 2023 Annual Meeting

June 27, 2023 — Helen Nadel, MD, FRCPC, director of pediatric nuclear medicine at Lucile Packard Children’s Hospital at ...

Time June 27, 2023
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now